Benefits of baked milk oral immunotherapy in French children with cow's milk allergy

De

Benefits of baked milk oral immunotherapy in French children with cow's milk allergy


Authors: 
Vianney Gruzelle, Agnès Juchet, Audrey Martin-Blonde, Marine Michelet, Anne Chabbert-Broue, Alain Didier

Abstract: 
Background: Introduction and gradual incremental escalation of a low dose of baked milk may accelerate the resolution of severe cow's milk (CM) allergy for some children. The purpose of our study was to evaluate the efficacy and safety of baked milk oral immunotherapy (OIT) in children with CM allergy after a low-dose baked milk oral food challenge (OFC). Methods: In a retrospective analysis of OFC performed between 2013 and 2018 at the Children's Hospital of Toulouse (France), we identified 64 children with CM allergy and high milk and casein-specific IgE levels, who underwent a total of 171 milk OFC. Mean age at 1st OFC was 4.8 years. Mean CM-specific IgE was 47.9 kUA/L, and mean casein-specific IgE was 42.3 kUA/L. Results: Most children were treated with baked milk OIT. Our study shows that 67.2% of the children did not react to 1st low-dose baked milk OFC (168.6 mg of CM protein). Eighteen percent of children stopped the OIT at home. Finally, desensitization to fresh milk was achieved in 27 children (42.2% of children allergic to CM). Children with lower CM-specific IgE levels have a significantly higher probability of becoming desensitized to unbaked CM. Conclusion: Most children with CM allergy and high milk and casein-specific IgE levels tolerate the introduction of baked milk. However, the occurrence of anaphylactic reactions during OIT remains possible.

Comentarios

Publicar un comentario

Entradas populares de este blog

Contact urticaria: Frequency, elicitors and cofactors in three cohorts (Information Network of Departments of Dermatology; Network of Anaphylaxis; and Department of Dermatology, University Hospital Erlangen, Germany)

De
Contact urticaria: Frequency, elicitors and cofactors in three cohorts (Information Network of Departments of Dermatology; Network of Anaphylaxis; and Department of Dermatology, University Hospital Erlangen, Germany) Authors: Helene Süß, Sabine Dölle-Bierke,  Johannes Geier, Burkhard Kreft, Eva Oppel, Claudia Pföhler, Christoph Skudlik, Margitta Worm, Vera Mahler Abstract:   Background: Contact urticaria (CU) is an infrequent, mostly occupational disease that may be life-threatening (CU syndrome stage 4). Objectives: To identify the current frequency, elicitors and cofactors of CU. Patients: Three cohorts were retrospectively analysed for CU: (a) patients from the Information Network of Departments of Dermatology (IVDK) database (2000-2014; n = 159 947); (b) patients from an allergy unit (Department of Dermatology, University Hospital Erlangen, 2000-2015; n = 4741); and (c) patients from the Anaphylaxis Registry (2007-2015: 6365 reported cases, including 2473 patients with Ring and Mes
Leer más

ICON: Diagnosis and management of allergic conjunctivitis. Miércoles 25 de marzo

De
ICON: Diagnosis and management of allergic conjunctivitis. Authors: Bielory L1, Delgado L2, Katelaris CH3, Leonardi A4, Rosario N5, Vichyanoud P6. Author information Abstract Ocular allergy (OA), interchangeably known as allergic conjunctivitis, is a common immunological hypersensitivity disorder affecting up to 40% of the population. Ocular allergy has been increasing in frequency, with symptoms of itching, redness, and swelling that significantly impacts an individual's quality of life (QOL). Ocular allergy is an often underdiagnosed and undertreated health problem, because only 10% of patients with OA symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary nonpharmacological remedies. The clinical course, duration, severity, and co-morbidities are varied and depend, in part, on the specific ocular tissues that are affected and on immunologic mechanism(s) involved, both local and systemic. It is frequently associat
Leer más

Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19).

De
 Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19).  Fecha de actualización: viernes 20 de marzo 2020 Versión: 7 1. Introducción El 31 de diciembre de 2019 la Comisión Municipal de Salud y Sanidad de Wuhan (provincia de Hubei, China) informó sobre un agrupamiento de 27 casos de neumonía de etiología desconocida con inicio de síntomas el 8 de diciembre; los casos reportaban antecedente de exposición común a un mercado de mariscos, pescados y animales vivos en la ciudad de Wuhan. El 7 de enero de 2020, las autoridades chinas identificaron como agente causante del brote un nuevo tipo de virus de la familia Coronaviridae, que fue denominado “nuevo coronavirus”, SARS-COV-2 (1). Dado que los casos de coronavirus suelen causar síntomas respiratorios, la Organización Mundial de la Salud (OMS) ha emitido recomendaciones de protección pers
Leer más